Jefferies lowered the firm’s price target on HCA Healthcare (HCA) to $525 from $590 and keeps a Buy rating on the shares. Jefferies noted that cold weather negatively impacted Q1 margins, but the firm is maintaining its Buy rating due to “upcoming SDP approvals, savings/productivity gains from “resiliency” program, and strong free cash flow.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Midday Fly By: Intel reports big beat, Meta to deploy AWS chips
- Morning Movers: Intel, MaxLinear skyrocket following first quarter reports
- HCA Healthcare Posts Solid Q1 Results, Reaffirms 2026 Outlook
- HCA Healthcare reports Q1 EPS $7.15, consensus $7.15
- Options Volatility and Implied Earnings Moves Today, April 24, 2026